Author/Authors :
Cassoni, Andrea Odontostomatological Science and Maxillo facial Surgery Department - Sapienza University of Rome, Rome, Italy , Romeo, Umberto Odontostomatological Science and Maxillo facial Surgery Department - Sapienza University of Rome, Rome, Italy , Terenzi, Valentina Odontostomatological Science and Maxillo facial Surgery Department - Sapienza University of Rome, Rome, Italy , Della Monaca, Marco Odontostomatological Science and Maxillo facial Surgery Department - Sapienza University of Rome, Rome, Italy , Rajabtork Zadeh, Oriana Odontostomatological Science and Maxillo facial Surgery Department - Sapienza University of Rome, Rome, Italy , Raponi, Ingrid Odontostomatological Science and Maxillo facial Surgery Department - Sapienza University of Rome, Rome, Italy , Teresa Fadda, Maria Odontostomatological Science and Maxillo facial Surgery Department - Sapienza University of Rome, Rome, Italy , Polimeni, Antonella Odontostomatological Science and Maxillo facial Surgery Department - Sapienza University of Rome, Rome, Italy , Valentini, Valentino Odontostomatological Science and Maxillo facial Surgery Department - Sapienza University of Rome, Rome, Italy
Abstract :
Objective. The acronym MRONJ has been created in order to identify “Medication-Related Osteonecrosis of the Jaw,” observed
after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw
in a Chron’s disease patient following a course of Bisphosphonate and Adalimumab therapy has been recently described, so that it
has been supposed that also this medication could promote manifestation of osteonecrosis. Clinical Case. On August, 2014, a 63-
year-old female with a history of idiopathic arthritis treated with medical treatment with Adalimumab from 2010 to 2013 presented
referring pain in the right mandible. Results. This patient presented with nonexposed osteonecrosis of the jaw after placement,
on September, 2010, of four titanium fixtures in the mandible. Conclusions. The authors suggest that the biologic therapy with an
anti-TNF-𝛼 antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.
